# LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

> **NCT07370597** · — · RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 110 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07370597
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370597, "LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07370597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*